/PRNewswire/ Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical stage pharmaceutical company addressing serious diseases with significant unmet need.
Lipella Pharmaceuticals' LP-310 clinical stage asset is formulated for delivering active agents to the oral cavity for diseases of the mouth including oral lichen planus and oral graft-versus-host disease PITTSBURGH, Nov. 10, 2023 /PRNewswire/ Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical stage pharmaceutical company addressing serious diseases with significant unmet need based in Pittsburgh, PA, announced today that it has been granted "Orphan Drug Designation" from the U.S. Food
Spectrum Pharmaceuticals (NASDAQ:SPPI – Get Free Report) and Lipella Pharmaceuticals (NASDAQ:LIPO – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability. Earnings and Valuation This table compares Spectrum […]
Lipella Pharmaceuticals’ (NASDAQ:LIPO – Get Rating) lock-up period will expire on Monday, June 19th. Lipella Pharmaceuticals had issued 1,217,391 shares in its IPO on December 20th. The total size of the offering was $6,999,998 based on an initial share price of $5.75. Shares of the company owned by company insiders and major shareholders will be […]
Lipella Pharmaceuticals’ (NASDAQ:LIPO – Get Rating) lock-up period will expire on Monday, June 19th. Lipella Pharmaceuticals had issued 1,217,391 shares in its public offering on December 20th. The total size of the offering was $6,999,998 based on an initial share price of $5.75. After the expiration of Lipella Pharmaceuticals’ lock-up period, restrictions preventing company insiders […]